

**APCCC Detailed Programme 2019 (subject to changes)**

Areas of controversy

- Areas of controversy
- Locally advanced prostate cancer
- Biochemical recurrence of prostate cancer after local therapy
- Management of primary tumour in the metastatic situation
- Systemic treatment castration-sensitive/naive prostate cancer
- Management of M0 castration-resistant prostate cancer
- Management of M1 castration-resistant prostate cancer
- Bone and bone metastases
- Molecular characterization: Tissue and blood
- Heterogeneity of men with prostate cancer (ethnicity, elderly, organ dysfunction)
- Side effects of hormonal treatments and their management

**Thursday 29<sup>th</sup> August 2019**

**Welcome Address**

**09:00 – 09:15** Silke Gillessen and Aurelius Omlin on behalf of APCCC

**09:15 – 10:30** **State of the art overview on molecular biomarkers and imaging in APC**  
**Session 1**

**Locally advanced prostate cancer**

(Staging and novel imaging, treatment of men with cN+ or pN+

**11:00 – 12:30** prostate cancer, systemic therapy including ADT plus novel endocrine agents and/or Docetaxel)  
**Session 2**

**PSA recurrence after local therapy**

(Staging and novel imaging, salvage therapy options,

**13:30 – 15:00** oligometastatic recurrence, systemic therapy)  
**Session 3**

**Germline mutations and Somatic mutations**

(genetic counselling, management of germline or somatic

**15:30 – 16:30** mutations)  
**Session 4**

**Influence of ethnicity and age in prostate cancer**

(Pharmaco-ethnicity, onco-geriatric assessment and treatment

**17:00 – 18:15** recommendations)  
**Session 5**

**Friday 30<sup>th</sup> August 2019**

**08:00 – 08:20** **Outcomes Research – Ironman project**

**Management of metastatic castration-sensitive/naive prostate cancer** (local treatment of the primary, ADT plus combinations,

**08:30 – 10:00** follow-up on ADT plus combinations, newly diagnosed

**Session 6** oligometastatic and oligoprogressive disease)

**Management of castration-resistant prostate cancer (CRPC)**

(sequencing, mechanisms of resistance to abiraterone or

enzalutamide, PSMA targeted therapies, PARP inhibition,

**10:30 – 12:30** immunotherapies, neuroendocrine spectrum and treatment,

**Session 7** radium-223)

**13:30 – 14:30** **Side effects of treatment and their management**

**Session 8** (PROs, sexuality, incontinence, hot flashes, metabolic changes)

**Bone and bone metastases**

(prevention/osteoporosis, antiresorptive therapy in CRPC,

**15:00 – 16:30** radium-223 plus bone health agents)  
**Session 9**

**17:00 – 18:30** **Outlook Session: What will change for men with advanced**

**Session 10** prostate cancer in the next 24 months?

**Saturday 31<sup>st</sup> of August 2019**

**Consensus Panel –**

**Discussion and votes on consensus questions Part 1**

All participants will be able to attend the panel meeting as part of the conference.

**08:30 – 10:30**

**Consensus Panel –**

**Discussion and votes on consensus questions Part 2**

All participants will be able to attend the panel meeting as part of the conference.

**11:00 – 13:00**